- Previous Close
6.40 - Open
6.00 - Bid 6.30 x --
- Ask 6.60 x --
- Day's Range
5.10 - 7.48 - 52 Week Range
4.60 - 15.00 - Volume
45,987 - Avg. Volume
105,566 - Market Cap (intraday)
298.654M - Beta (5Y Monthly) -0.52
- PE Ratio (TTM)
-- - EPS (TTM)
-1.79 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.81
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
www.lytixbiopharma.comRecent News: LYTIX.OL
View MorePerformance Overview: LYTIX.OL
Trailing total returns as of 11/6/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LYTIX.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LYTIX.OL
View MoreValuation Measures
Market Cap
317.51M
Enterprise Value
260.32M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
18.81
Price/Book (mrq)
5.36
Enterprise Value/Revenue
18.02
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-53.28%
Return on Equity (ttm)
-105.16%
Revenue (ttm)
14.44M
Net Income Avi to Common (ttm)
-76.42M
Diluted EPS (ttm)
-1.79
Balance Sheet and Cash Flow
Total Cash (mrq)
60.18M
Total Debt/Equity (mrq)
5.06%
Levered Free Cash Flow (ttm)
-58.68M